Ask AI
ProCE Banner Events

Share

Evening With the Experts: Next Generation Predictive Biomarkers and Targeted Therapies in GI Cancers

Join us for this case-based, interactive, CME-certified symposium held in conjunction with the 2023 Gastrointestinal Cancers Symposium featuring expert perspectives on molecular testing, predictive biomarkers, and targeted therapy for patients with GI malignancies. Bring your questions for the live Q&A session with the expert panel at the end of the session.

maximum of 1.50 AMA PRA Category 1 Credits™

This event has expired. No longer available for credits.

Who Should Attend

This educational program is intended for medical oncologists and other healthcare professionals who treat patients with gastrointestinal cancers.

Time and location

Wednesday, January 18, 2023

6:30 PM - 8:30 PM Pacific Time (PT)

Virtual

Agenda

  • Welcome and Overview
  • Barriers to Precision Medicine for GI Cancers
  • Case Discussions: Updates in Biomarker Testing and Targeted Therapy Across GI Cancers
    • Actionable biomarkers: who to test and what to test for
    • Expert targeted treatment recommendations
  • Live Audience Question and Answer Session

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in the assessment of predictive biomarkers to guide the individualized treatment of patients with gastrointestinal malignancies.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Implement evidence-based molecular testing in GI cancers, including BRAF V600E, HER2/HER3, BRCA1/2, FGFR2, IDH1, and histology-agnostic markers
  • Plan targeted therapeutic strategies for patients with GI malignancies based on predictive biomarker assessment, available data, and expert recommendations
  • Counsel patients about their tumor molecular profile and how this information will guide therapy decisions
  • Identify patients with GI malignancies eligible for enrollment in ongoing clinical trials of novel biomarker-driven treatment strategies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by an educational grant from:

Astellas
AstraZeneca
Elevation Oncology, Inc.
Merck Sharp & Dohme Corp.
Merus NV
Seagen Inc.

Contact Information

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.